Vical's TransVax CMV Vaccine Achieves Statistical Significance on Key Clinical Endpoints in Phase 2 Trial
Conference Call and Webcast Concurrent With ICAAC Presentation at 11:15 a.m. EDT Tuesday
SAN DIEGO, Sept. 13, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.
"The TransVax™ vaccine has demonstrated the ability to drive effective immune responses in the inherently difficult therapeutic setting of immunocompromised patients," said CMV and organ transplant expert Mark D. Pescovitz, M.D. "In addition to providing evidence of protective efficacy in HCT recipients, the TransVax™ Phase 2 results have identified clinically relevant endpoints that may be appropriate for further development."
"We look forward to finalizing our approach through discussions with CMV and transplant experts, and reviewing our resulting plans with the regulatory agencies," said Richard T. Kenney, M.D., Vical's Vice President of Clinical Development, who will present the data at 11:15 a.m. EDT Tuesday at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Boston – September 12-15). Dr. Pescovitz, Professor of Surgery and Microbiology & Immunology, and Vice Chair of Research in Surgery at the Indiana University School of Medicine, will join Vical management on a concurrent conference call and webcast for the investment community.
The TransVax™ Phase 2 trial was a 1:1 randomized, double-blind, placebo-controlled, multi-center study in 80 patients scheduled to receive HCTs for their underlying leukemias or lymphomas. Through 12 months post-transplant, significant reductions were achieved for key viral reactivation metrics:
* The incidence of CMV viremia (percentage of subjects with =500 copies of CMV virus per mL of blood by a central lab assay) was 32% in the TransVax™ group, and 62% in the placebo group (p=0.008); * The median time to initial viremia was >365 days (i.e., median not reached during the 12-month study period) for the TransVax™ group, and 109.5 days for the placebo group (p=0.003); * The number of CMV viremia episodes (0-4 per subject) was significantly lower for the TransVax™ group than for the placebo group (p=0.017); * The duration of viremia was lower for the TransVax™ group than for the placebo group (mean of 10.6 days vs. mean of 19.5 days, respectively; p=0.069), and significantly lower as a percentage of the time subjects spent on study (mean of 4.9% vs. mean of 7.7%, respectively; p=0.042); and * The prevalence of CMV viremia episodes over the trial period was significantly lower for the TransVax™ group than for the placebo group (p=0.036).
Antiviral therapy use was triggered by site-specific treatment practices based on local lab assays, which impeded comparability among the 16 enrolling U.S. sites. Overall, 48% of subjects in the TransVax™ group vs. 62% of subjects in the placebo group received antiviral drugs for CMV during the study. The median duration of antiviral treatment was approximately 30 days in the TransVax™ group vs. approximately 40 days in the placebo group. Because antiviral drugs are used preemptively to control CMV outbreaks, CMV-associated disease is rare and the study was not powered to detect a difference in this endpoint. Only three of 40 subjects (8%) in the TransVax™ group and four of 34 subjects (12%) in the placebo group developed CMV-associated disease. Antiviral drug usage and CMV-associated disease are not practical endpoints for future studies.
Published data have shown that T-cell responses are critical for controlling CMV reactivation; antibody responses may provide additional protection. The HCT recipients in the study all had preexisting CMV infections and therefore would be expected to have baseline immune responses against CMV. They were also immunosuppressed as a result of treatments for their underlying leukemias or lymphomas. Despite these challenges:
* T-cell responses to phosphoprotein 65 (pp65) were significantly higher in the TransVax™ group than in the placebo group over the one-year trial (p=0.003); and * T-cell and antibody responses to glycoprotein B (gB) were higher in the TransVax™ group than in the placebo group and trending toward greater separation over the one-year trial.
The TransVax™ vaccine was well tolerated in the Phase 2 trial in immunocompromised HCT recipients, and no safety concerns were raised during the trial. There was no significant difference in the number of serious adverse events (SAEs) between the TransVax™ and placebo groups. There also were fewer deaths in the TransVax™ group (18%) than in the placebo group (32%) during the trial.
Phase 2 Trial Design
The Phase 2 trial evaluated the potential for TransVax™ to control CMV reactivation in immunosuppressed CMV-seropositive HCT recipients, which could reduce antiviral usage and CMV-associated disease. Subjects were randomized by site, transplant donor CMV-seropositive or -seronegative status, and donor/recipient genetic match (matching either 5 of 6 or 6 of 6 human leukocyte antigen alleles) and received either the TransVax™ vaccine or placebo shortly before the transplant and again at approximately 1, 3 and 6 months post-transplant. The study was conducted at 16 U.S. sites, and the endpoints evaluated for 12 months post-transplant included safety, immunogenicity, use of CMV antiviral therapy, and viral load.
TransVax™ is a bivalent DNA vaccine containing plasmids (closed loops of DNA) encoding CMV pp65 and gB antigens for induction of both cellular and humoral immune responses. TransVax™ is formulated with a proprietary poloxamer-based delivery system. TransVax™ has received orphan drug designation in the United States for HCT and solid organ transplant patients.
Vical will conduct an audio-only conference call and audio/slide
webcast at 11:15 a.m. EDT Tuesday to discuss details of the results
with invited analysts and institutional investors. The call is open
on a listen-only basis to any interested parties. The webcast audio
and slides also will be available live and archived through the
Events page of the company's website at
Vical researches and develops biopharmaceutical products based
on its patented DNA delivery technologies for the prevention and
treatment of serious or life-threatening diseases. Potential
applications of the company's DNA delivery technology include DNA
vaccines for infectious diseases or cancer, in which the expressed
protein is an immunogen; cancer immunotherapeutics, in which the
expressed protein is an immune system stimulant; and cardiovascular
therapies, in which the expressed protein is an angiogenic growth
factor. The company is developing certain infectious disease
vaccines and cancer therapeutics internally. In addition, the
company collaborates with major pharmaceutical companies and
biotechnology companies that give it access to complementary
technologies or greater resources. These strategic partnerships
provide the company with mutually beneficial opportunities to
expand its product pipeline and address significant unmet medical
needs. Additional information on Vical is available at
The Vical Incorporated logo is available at
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about Vical's technologies, the TransVax™ vaccine effectiveness in reducing key CMV reactivation metrics, as well as the company's focus, collaborative partners, and independent and partnered product candidates. Risks and uncertainties include whether Vical or others will continue development of TransVax™ or any other product candidates; whether endpoints identified in or as a result of the Phase 2 trial will be acceptable to the relevant regulatory agencies; whether Phase 2 results will be predictive of results in any future studies; whether Vical or others will advance TransVax™ to Phase 3 testing; whether such testing, if conducted, will be successful; whether Vical or its collaborative partners will seek or gain approval to market TransVax™ or any other DNA-based human vaccine or therapeutic product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
CONTACT: Vical Incorporated Alan R. Engbring (858) 646-1127
Posted: September 2010